Triple-negative breast cancer (TNBC) metastasizes and is currently associated with poor prognosis and lack of effective targeted therapies. We are studying the potential of Deferiprone, an intracellular iron chelator clinically used for non-cancer-related diseases, to improve the chemotherapeutic treatment response in TNBC by altering cellular iron-dependent proliferation and metabolism. Here, cellular and energy metabolism changes in response to Deferiprone were assayed in live TNBC cells by multi-nuclear MRS in our MR-compatible bioreactor. Metabolic changes in a human TNBC cell line are compared to previous findings in murine TNBC cells.
This abstract and the presentation materials are available to members only; a login is required.